A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants With Primary Mitochondrial Myopathy
Latest Information Update: 04 Sep 2024
Price :
$35 *
At a glance
- Drugs Bocidelpar (Primary)
- Indications Mitochondrial myopathies
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms MOUNTAINSIDE
- Sponsors Astellas Pharma
- 10 Jun 2024 Status changed from active, no longer recruiting to discontinued.
- 19 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2023 Planned End Date changed from 31 May 2024 to 30 Nov 2025.